Payment overview · 2025
General Payments
$65.17
3 reported records · 3 companies
Healthcare provider profile · identity verified
David Thomas Potter, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · SPOKANE, WA · NPI 1396759197
Verified facts
What the public records show
CMS Open Payments records show David Thomas Potter, MD received $65.17 in general payments during 2025 across 3 reported records.
Alkermes, Inc. accounted for 37.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Aristada, Ingrezza.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Aristada by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Abilify Maintena by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ingrezza by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $24.28 | 37.3% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $21.16 | 32.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.73 | 30.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $65.17 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $19.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ARISTADA aristada |
2025 | Aristada | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Olanzapine | Olanzapine | 453 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 247 | 28 |
| Clozapine | Clozapine | 234 | 12 |
| Sertraline Hcl | Sertraline Hcl | 218 | 26 |
| Trazodone Hcl | Trazodone Hcl | 216 | 39 |
| Aripiprazole | Aripiprazole | 206 | 29 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 187 | 46 |
| Benztropine Mesylate | Benztropine Mesylate | 169 | 21 |
| Buspirone Hcl | Buspirone Hcl | 168 | 21 |
| Invega Sustenna | Paliperidone Palmitate | 154 | 15 |
| Bupropion Xl | Bupropion Hcl | 152 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 141 | 18 |
| Paliperidone Er | Paliperidone | 139 | 14 |
| Risperidone | Risperidone | 128 | 17 |
| Prazosin Hcl | Prazosin Hcl | 123 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 117 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 104 | suppressed |
| Lorazepam | Lorazepam | 101 | 15 |
| Clonazepam | Clonazepam | 99 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 14 |
| Mirtazapine | Mirtazapine | 91 | 17 |
| Divalproex Sodium Er | Divalproex Sodium | 90 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 84 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 13 |
| Clonidine Hcl | Clonidine Hcl | 75 | 11 |
| Lamotrigine | Lamotrigine | 71 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 69 | suppressed |
| Gabapentin | Gabapentin | 66 | 12 |
| Diazepam | Diazepam | 60 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 60 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | suppressed |
| Belsomra | Suvorexant | 56 | 11 |
| Vraylar | Cariprazine Hcl | 56 | suppressed |
| Haloperidol | Haloperidol | 51 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 50 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 48 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 47 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 46 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 37 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 36 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 35 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 31 | suppressed |
| Amantadine | Amantadine Hcl | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Ramelteon | Ramelteon | 25 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Abilify Maintena | Aripiprazole | 16 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Perphenazine | Perphenazine | 16 | suppressed |
| Aristada | Aripiprazole Lauroxil | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Fetzima | Levomilnacipran Hcl | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Dayvigo | Lemborexant | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $65.17 · 3 records | Alkermes, Inc. | ARISTADA, INGREZZA, LYBALVI, REXULTI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Aristada play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Alkermes, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error